AAO links timing to RVO outcomes

1/ AAO’s latest retina coverage centers on a familiar clinical problem: two patients can have similar OCT thickness in retinal vein occlusion, but very different visual outcomes. A new Ophthalmology Retina analysis asked whether part of that difference is visible much earlier — at baseline vision and in the interval between diagnosis and first treatment. 2/ The study looked at macular edema after branch or central retinal vein occlusion treated with intravitreal aflibercept 2 mg. Its stated aim was to examine how time from diagnosis to first injection, together with baseline best-corrected visual acuity, affected visual and anatomic outcomes. 3/ The headline finding is straightforward: shorter time from diagnosis to treatment was associated with better visual results, and eyes that started with better baseline vision also did better. (sciencedirect.com) That does not rewrite RVO care, but it sharpens a point retina specialists already confront in clinic — delay matters, and starting point matters. 4/ AAO’s own 2024 Preferred Practice Pattern already places intravitreal anti-VEGF agents as first-line treatment for macular edema associated with both branch and central retinal vein occlusions. (sciencedirect.com) The new analysis fits inside that framework by focusing less on whether anti-VEGF works than on which patients are positioned to recover more vision once treatment begins. 5/ Why would timing show up so strongly in a post hoc analysis? (sciencedirect.com) RVO is not a single clinical state. The AAO Preferred Practice Pattern says prognosis varies by site of occlusion and by whether the event is ischemic or nonischemic, with more-distal occlusions generally faring better than more-proximal, more ischemic disease. 6/ That matters because a patient who reaches treatment later may not just have “the same disease, later.” By the time injections start, the eye may already reflect more sustained edema, more ischemic injury, or less recoverable retinal function. (aao.org) The study’s framing suggests baseline vision is acting partly as a readout of that starting damage burden. That is an inference from the paper’s design and the AAO guideline language on prognosis. 7/ The story also sits next to a second AAO education push on the same disease. AAO has posted a CME course, “Management of RVO With Macular Edema,” in which Michael Ip presents a case on patients who need monthly or near-monthly therapy and describes anatomic biomarkers that may explain worsening visual acuity even when OCT central subfield thickness remains stable. 8/ That CME framing helps explain why the timing analysis is getting attention now. (sciencedirect.com) In practice, retina specialists are often trying to reconcile three different signals at once: when the patient first presented, how much vision was already lost, and whether OCT alone is capturing the reason vision is not recovering as expected. 9/ The broader anti-VEGF discussion has also moved on to durability. A Modern Retina panel with Sharon Fekrat, Jorge Fortun and John Kitchens compared aflibercept 8 mg with faricimab in RVO and said trial results for both agents showed robust visual and anatomic gains, while emphasizing that outcomes were strongest when treatment began early and was delivered consistently. (aao.org) 10/ For clinicians, the immediate takeaway is not a change in drug hierarchy. (sciencedirect.com) It is a reminder that the first decisions in RVO — how fast a patient is referred, how quickly injections begin, and how baseline vision is framed in counseling — may shape the ceiling for recovery before any durability debate starts. The underlying analysis is published in Ophthalmology Retina, and AAO’s Michael Ip CME module is already live on the Academy’s education site. (modernretina.com)